Rhythm Metabolic

Rhythm Metabolic is a biopharmaceutical company developing peptide therapeutics for the treatment of obesity, including obesity caused by genetic defects in the MC4 pathway and Prader-Willi syndrome.

Deerfield invested as part of a Series A Convertible Preferred financing of $40M. This capital will allow Rhythm to advance its lead product candidate in a Phase 2a clinical trial in Prader-Willi syndrome.